Yang, Chih-JenChih-JenYangWei, Yu-JuiYu-JuiWeiChang, Hsu-LiangHsu-LiangChangChang, Pi-YuPi-YuChangTsai, Chung-ChenChung-ChenTsaiChen, Yen-HsuYen-HsuChenPO-REN HSUEH2021-04-232021-04-232021-0216841182https://scholars.lib.ntu.edu.tw/handle/123456789/557663Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).enCompassionate use; Coronavirus disease 2019; Remdesivir; Severe acute respiratory syndrome coronavirus 2[SDGs]SDG3alanine aminotransferase; angiotensin receptor antagonist; azithromycin; chloroquine; colchicine; convalescent plasma; corticosteroid; dipeptidyl carboxypeptidase inhibitor; favipiravir; hemoglobin; hydroxychloroquine; ibuprofen; indometacin; interferon; lopinavir plus ritonavir; placebo; remdesivir; ribavirin; tocilizumab; adenosine phosphate; alanine; antivirus agent; remdesivir; acute respiratory failure; anemia; antiviral activity; artificial ventilation; constipation; coronavirus disease 2019; drug efficacy; drug mechanism; drug withdrawal; estimated glomerular filtration rate; evidence based medicine; headache; human; hyperbilirubinemia; hypertransaminasemia; hypoalbuminemia; hypokalemia; hypotension; kidney failure; loading drug dose; lower respiratory tract infection; maculopapular rash; multicenter study (topic); nausea; nonhuman; oxygen therapy; pandemic; phase 3 clinical trial (topic); preclinical study; randomized controlled trial (topic); Review; thrombocytopenia; virus pneumonia; China; clinical trial (topic); drug effect; drug therapy; epidemiology; pandemic; Adenosine Monophosphate; Alanine; Antiviral Agents; China; Clinical Trials as Topic; COVID-19; Humans; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2review10.1016/j.jmii.2020.09.002330600412-s2.0-85092537252https://scholars.lib.ntu.edu.tw/handle/123456789/528152